Holocene Advisors
ARQT icon

Holocene Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

Holocene Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,204,538
Closed -$6.4M – 699
2023
Q3 		$6.4M Sell
1,204,538
-235,498
-16% -$2M 0.03% 347
2023
Q2 		$13.7M Sell
1,440,036
-629,141
-30% -$6.98M 0.06% 237
2023
Q1 		$22.8M Buy
2,069,177
+924,034
+81% +$13.4M 0.11% 190
2022
Q4 		$16.9M Buy
1,145,143
+1,004,141
+712% +$17.5M 0.1% 201
2022
Q3 		$2.69M Buy
+141,002
New +$3.19M 0.02% 363

Other funds holding ARQT

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Holocene Advisors's ARQT Position: Q4 2023 in Review

Holocene Advisors sold out of Arcutis Biotherapeutics (ARQT) in Q4 2023, closing a stake of 1,204,538 shares — an estimated $6.4M sold.

Holocene Advisors first reported a position in ARQT in Q3 2022 and held it in 5 quarters. The position peaked at $22.8M in Q1 2023. 133 funds tracked by Wall St. Rank hold ARQT as of Q4 2023.

  • Holocene Advisors reported no remaining Arcutis Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Holocene Advisors sold 1,204,538 Arcutis Biotherapeutics shares in Q4 2023, an estimated $6.4M.
  • Holocene Advisors first reported a position in Arcutis Biotherapeutics in Q3 2022 and held it in 5 quarters.
  • Holocene Advisors's Arcutis Biotherapeutics position peaked at $22.8M in Q1 2023.
  • 133 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2023.

Based on Holocene Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.